Can you name the lurbinectedin induced adverse events that led to interruptions?

Which adverse events most often caused lurbinectedin dose interruptions?
Myelosuppression events—specifically neutropenia, thrombocytopenia, and anemia—were the main drivers. Neutropenia alone triggered roughly one-third of all interruptions, with grade 3–4 neutrophil counts dropping below 1,000 cells/µL in 46% of patients and below 500 cells/µL in 20% [1].

What laboratory thresholds trigger these pauses?
Treatment is held when absolute neutrophil count falls below 500 cells/µL, platelet count below 50,000 cells/µL, or hemoglobin below 8 g/dL, with resumption only after counts recover to acceptable levels [1].

How long do interruptions typically last?
Most patients resume dosing within one to two weeks once counts rebound, though repeated cycles may require permanent dose reductions to avoid recurrent delays [1].

Are there other reasons for holding therapy?
Non-hematologic events such as fatigue, nausea, and elevated liver enzymes also prompted interruptions, but they accounted for far fewer cases than blood-count abnormalities [1].

How does this compare with other agents in small-cell lung cancer?
The pattern mirrors topotecan, where myelosuppression likewise dominates dose delays, but lurbinectedin’s overall discontinuation rate due to adverse events remains lower (about 10%) than historical topotecan data [1].

What monitoring reduces the need for interruptions?
Weekly complete blood counts during the first two cycles, followed by counts before each cycle, allow early growth-factor support or dose adjustments that keep most patients on schedule [1].

[1] DrugPatentWatch.com – Lurbinectedin (Zepzelca) prescribing information and safety data.